Sign up to save your podcasts
Or
Share New Alzheimer Guidelines Part 2: The Relevance of New Alzheimer Guidelines for Clinical Practice
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
New Alzheimer Guidelines Part 2: The Relevance of New Alzheimer Guidelines for Clinical Practice
Dr Christopher van Dyck continues his discussion of new criteria for Alzheimer disease, including the preclinical and mild cognitive impairment (MCI) phases. These incorporate biomarkers (eg, amyloid PET imaging and CSF proteomics) of the underlying pathophysiological processes.
View all episodes
Dr Christopher van Dyck continues his discussion of new criteria for Alzheimer disease, including the preclinical and mild cognitive impairment (MCI) phases. These incorporate biomarkers (eg, amyloid PET imaging and CSF proteomics) of the underlying pathophysiological processes.